Across TCGA pan-cancer cohorts, RGS7BP Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RGS7BP data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RGS7BP Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RGS7BP expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

HNSC, LUAD, and UCEC are the cancer types where RGS7BP Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.199	0.768	.002	24	view →
LUAD	DFS	Median	All	0.098	0.768	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	DFS	Median	II,III,IV	0.139	0.712	<.001	6	view →
LUSC	OS	Median	All	1.000	0.395	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RGS7BP tumor-vs-normal RNA expression · all RGS7BP data types